HELX vs WDNA: Holdings Overlap & Returns
Over the year to Nov 13, 2026, HELX returned +22.6% to WDNA's +43.3%; 33% of their weight is in the same names.
- Return gap
- +20.7 pts1 year to Nov 13, 2026: WDNA ahead, total return
- Fee gap
- 0.05 ptsA year: HELX 0.50%, WDNA 0.45%, per filings dated Jul 27, 2026 and Oct 28, 2026
- Overlap
- 33%Share of the two books held in common, holdings dated Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
HELX +22.6%, WDNA +43.3%: WDNA +20.7 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Fees over time
Hypothetical. $10,000 in HELX for 10 years at 0.50% a year costs about $827 in fees and lost growth; WDNA at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
15% of HELX's weight is in S&P 500 companies and 85% is outside the index. Holdings as of Jun 30, 2026.
26% of WDNA's weight is in S&P 500 companies and 74% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
WDNA costs 0.05 points a year less; their one-year returns differ by 20.7 points.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +22.6% | +43.3% |
|---|---|---|
| Below its all-time high | 26.5%, high on Sep 7, 2021 | 13.9%, high on Sep 2, 2021 |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.50% | 0.45% |
| Net assets, HELX as of Nov 12, 2026 and WDNA as of Jun 30, 2026 | $34m | $2.7m |
| Holdings in common | 33% |
The numbers behind it
Net assets: $34m on Nov 12, 2026 for Franklin Genomic Advancements ETF, and $2.7m on Jun 30, 2026 for WisdomTree BioRevolution Fund.
Holdings in common uses holdings dated Jun 30, 2026.
What they share
By the books each fund has filed, HELX and WDNA hold 33% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026.
half
33% in common
Held in common
Show all 12 holdings
| ELI LILLY & COMPANY | 2.95% | 4.08% |
| TWIST BIOSCIENCE CORP | 2.85% | 5.95% |
| UNITED THERAPEUTICS CORP | 3.51% | 2.45% |
| NATERA INC | 7.46% | 2.32% |
| CORTEVA INC | 2.25% | 1.99% |
| KRYSTAL BIOTECH INC | 6.33% | 1.96% |
| TEMPUS AI INC | 1.95% | 2.28% |
| IONIS PHARMACEUTICALS INC | 1.91% | 1.86% |
| ASTRAZENECA PLC | 2.70% | 1.83% |
| VERACYTE INC | 1.64% | 1.46% |
| VERTEX PHARMACEUTICALS INC | 2.75% | 1.34% |
| STOKE THERAPEUTICS INC | 1.33% | 2.09% |
Only in HELX
Show all 8 holdings
| GUARDANT HEALTH INC | 9.09% |
| LIGAND PHARMACEUTICALS INC | 4.62% |
| ADAPTIVE BIOTECHNOLOGIES CORP | 3.99% |
| TRAVERE THERAPEUTICS INC | 2.59% |
| SAMSUNG BIOLOGICS CO LTD | 2.26% |
| MEDPACE HOLDINGS INC | 2.15% |
| NEUROCRINE BIOSCIENCES INC | 1.84% |
| ARGENX SE | 1.64% |
Only in WDNA
Show all 8 holdings
| MODERNA INC | 4.14% |
| JOHNSON & JOHNSON | 2.97% |
| IMMUNOME INC | 2.26% |
| STRUCTURE THERAPEUTICS INC | 2.12% |
| DARLING INGREDIENTS INC | 1.94% |
| 10X GENOMICS INC | 1.81% |
| ROIVANT SCIENCES LTD | 1.73% |
| ABSCI CORP | 1.71% |
Side by side
Open the table
| Fund | Franklin Genomic Advancements ETF · Holds 61 stocks in healthcare innovation and GLP-1, 15% of its weight in S&P 500 companies | WisdomTree BioRevolution Fund · Holds 80 stocks in healthcare innovation and GLP-1, 26% of its weight in S&P 500 companies |
| Issuer | Franklin | WisdomTree |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 14.9% | 25.9% |
| Active share vs the S&P 500 | 97.2% | 95.3% |
| In the Nasdaq-100 | 7.5% | 5.2% |
| Holdings | 61 | 80 |
| Top ten, share of the fund | 47.1% | 30.7% |
| Expense ratio | 0.50% | 0.45% |
| Fee for the differing part | 0.51% | 0.47% |
| Total return, 1 year | +22.6% | +43.3% |
| vs its benchmark | not measured | not measured |
| Below its high | −26.5% | −13.9% |
| Net assets, HELX as of Nov 12, 2026 and WDNA as of Jun 30, 2026 | $34m | $2.7m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | +5.0% | +6.8% |
|---|---|---|
| 6 months | +29.7% | +30.6% |
| 1 year | +22.6% | +43.3% |
| 3 years | +57.1% | +62.5% |
| Since launch (Not the same days: HELX Feb 2020 · WDNA Jun 2021) | +78.8% | −3.7% |
About HELX
By weight, 15% of HELX's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 97%. The top ten holdings are 47% of the fund across 61 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +22.6% with distributions reinvested. It sits 26.5% below its all-time high of Sep 7, 2021.
About WDNA
By weight, 26% of WDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 95%. The top ten holdings are 31% of the fund across 80 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +43.3% with distributions reinvested. It sits 13.9% below its all-time high of Sep 2, 2021.
33% of the two portfolios are the same securities at the same weight.
Questions people ask
Do HELX and WDNA hold the same stocks?
By their latest filings, 33% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, HELX against WDNA, data as of Nov 13, 2026. https://etfiq.com/compare/themes/helx-vs-wdna
ETFIQ. (Nov 13, 2026). HELX against WDNA. Retrieved from https://etfiq.com/compare/themes/helx-vs-wdna
[HELX against WDNA (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/helx-vs-wdna)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.